Possible scenario
Momentum Extends
35% Chance
Investors treat the 663% return as confirmation that Moderna's post-Covid reset is working, not just a speculative rebound. FDA approval of its mRNA flu vaccine and positive melanoma-vaccine data with Merck keep attention on a broader platform recovery.
Secondary impacts
- Healthcare +0.3%
Tickers
- MRNA+5.3%
- PFE-0.7%
- MRK+0.2%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.